Stay updated on APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial
Sign up to get notified when there's something new on the APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial page.

Latest updates to the APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added, and notices about government funding lapse and operating status were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check20 days agoChange DetectedA government funding notice banner is displayed on the page, informing visitors of potential delays and status updates. The revision tag has been updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary display and a new 'Last Update Submitted that Met QC Criteria' field. The footer now shows 'No FEAR Act Data' and a 'Revision: v3.4.0' indicator.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This appears to be a metadata update with no impact on study details or content.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations section updated to add a consolidated list of study sites across California, Colorado, District of Columbia, Florida, Georgia, Indiana, Louisiana, Maryland, Missouri, New York, North Carolina, Tennessee, Virginia, and Wisconsin. A new Revision: v3.3.3 appears and older state-specific locations and the HHS Vulnerability Disclosure link were removed (Revision: v3.3.2).SummaryDifference1%

- Check92 days agoChange DetectedAdded a notice that publications are automatically filled from PubMed and that the revision is v3.3.2. Removed the previous notice describing PubMed-sourced publications and the older revision v3.2.0.SummaryDifference0.1%

Stay in the know with updates to APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APL-2 Safety & Efficacy in Glomerulopathies Clinical Trial page.